Another Trop-2 targeting ADC, DS-1062 (Daiichi Sankyo), which consists of a Trop-2 specific monoclonal antibody coupled with the topoisomerase inhibitor DXd, is yet to be investigated in prostate cancer, but is in early phase trials in NSCLC (NCT04484142, NCT04526691) and triple negative breast cancer (TNBC; NCT03401385) [81]. Here, TACSTD2 is linked to non-small cell lung carcinoma.